Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $61.8 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) rose 0.63% to $61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 0.63%. This contributed to the annual value of $61.4 million for FY2024, which is 22.67% up from last year.
  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) amounted to $61.8 million in Q3 2025, which was up 0.41% from $61.5 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) registered a high of $61.8 million during Q3 2025, and its lowest value of $49.4 million during Q1 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Shares Outstanding (Weighted Average) value was $50.5 million (recorded in 2024), while the average stood at $55.2 million.
  • Data for Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 23.59% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $50.1 million in 2023, then rose by 22.67% to $61.4 million in 2024, then grew by 0.63% to $61.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $61.8 million for Q3 2025, versus $61.5 million for Q2 2025 and $61.5 million for Q1 2025.